BALTIMORE--(BUSINESS WIRE)--Profectus BioSciences Inc., a leader in developing next generation vaccines for high value targets in biodefense, infectious, and emerging diseases, presented on the development of its rVSV-vectored Ebola and Marburg virus vaccine at the Filovirus Medical Countermeasures (MCM) Workshop held in the National Institutes of Health (NIH) Fishers Lane Conference Center in Rockville, MD. The two day meeting was sponsored by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID), the Food and Drug Administration (FDA), the Department of Defense Joint Vaccine Acquisition Program (DoD-JVAP), the Assistant Secretary for Preparedness and Response (ASPR), and the Biomedical Advanced Research and Development Authority (BARDA).
Help employers find you! Check out all the jobs and post your resume.
